The future of influenza vaccine production a lot of most likely lies along with cell culture-based processes. Cell-based units supply many conveniences over traditional egg-based production, consisting of rate of production, absence of dependence about egg supply, avoidance of egg allergens, greater very first purity, and capability to combine upstream and downstream in to an automated process.
Cell culture is well suited to rapid pandemic response since time-consuming recombination of the virus in to an egg-adjusted flu strain is no longer required. Cell-based procedures can easily thus make huge quantities of vaccine in a relatively short interval of time, given they can easily range up efficiently.
Growth of influenza virus in single-usage bioreactors and ways with regard to scaling up production are the topics of this article.
Influenza virus is usually grown about adherent cells such as the Madin-Darby puppy kidney (MDCK) cell line. These kinds of cells have actually traditionally been cultured utilizing 2D tissue culture flasks or roller bottles that are inefficient to range to business volumes. The Mobius® 3L single-usage stirred-tank bioreactor is a benchtop vessel appropriate with regard to cell-based vaccine procedure development. This tutorial focuses about the optimization of an MDCK cell-based influenza production procedure utilizing Cytodex® 3 and Cytodex 1 microcarriers in a Mobius 3L single-usage stir tank bioreactor and scale-up of this procedure to a Mobius 50L bioreactor (Figure 1).
from Influenza – NewsBlog http://ift.tt/29a45PW
